Special Issue "Antiviral Drugs 2021"
Deadline for manuscript submissions: 31 March 2022.
From the beginning of human civilization, viral infections have been part of human life, and still represent one of the greatest burdens for humans and society, with a huge devastating socioeconomic impact. Over the last year, a worst-case scenario of viral pandemic (i.e., severe acute respiratory syndrome coronavirus 2, SARS-CoV-2) has threatened millions of lives, while devastating the primal health care systems across the world. Fortunately, the advancement in the field of antiviral drug discovery over the last forty years led to the development of important therapies that intercept human immunodeficiency virus (HIV) replication or cure hepatitis C virus infections in people suffering from liver disease. Nevertheless, according to the World Health Organization (WHO), we are still a long way from achieving suitable treatments for other viral-infection-related diseases such as SARS, HBV, Influenza, and Ebola. Moreover, the emergence of drug resistance that threatens the efficacy of successful therapies used today and the lack of vaccines for many viral pathogens make the discovery and development of antiviral agents an unmet global need. Urged by this global crisis, the field has been involved in an unprecedented endeavor to enhance established antiviral strategies and develop novel and innovative approaches for new classes of antiviral agents targeting different life cycle pathways that are critical for the virus, including viral and host factors and new antiviral modalities.
In the present Special Issue entitled “Antiviral Drugs”, we are inviting the submission of original research articles, letters, and/or reviews from academia, research institutes, not-for-profit organizations, or industry that work on the identification, synthesis, and evaluation of direct-acting antiviral or host-targeting agents that inhibit viral replication or pathogenesis. Furthermore, we also welcome the submission of mechanistic studies of new small organic molecules, metal complexes, and natural products, as well as studies on drug resistance, the in silico design of antiviral agents, and antiviral target validation.
Prof. Dr. Grigoris Zoidis
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.